Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: A systematic review and meta-analysis of randomized trials

Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
American Journal of Clinical Nutrition (Impact Factor: 6.77). 03/2012; 95(3):740-51. DOI: 10.3945/ajcn.111.023457
Source: PubMed


There is substantial interest in chocolate and flavan-3-ols for the prevention of cardiovascular disease (CVD).
The objective was to systematically review the effects of chocolate, cocoa, and flavan-3-ols on major CVD risk factors.
We searched Medline, EMBASE, and Cochrane databases for randomized controlled trials (RCTs) of chocolate, cocoa, or flavan-3-ols. We contacted authors for additional data and conducted duplicate assessment of study inclusion, data extraction, validity, and random-effects meta-analyses.
We included 42 acute or short-term chronic (≤18 wk) RCTs that comprised 1297 participants. Insulin resistance (HOMA-IR: -0.67; 95% CI: -0.98, -0.36) was improved by chocolate or cocoa due to significant reductions in serum insulin. Flow-mediated dilatation (FMD) improved after chronic (1.34%; 95% CI: 1.00%, 1.68%) and acute (3.19%; 95% CI: 2.04%, 4.33%) intakes. Effects on HOMA-IR and FMD remained stable to sensitivity analyses. We observed reductions in diastolic blood pressure (BP; -1.60 mm Hg; 95% CI: -2.77, -0.43 mm Hg) and mean arterial pressure (-1.64 mm Hg; 95% CI: -3.27, -0.01 mm Hg) and marginally significant effects on LDL (-0.07 mmol/L; 95% CI: -0.13, 0.00 mmol/L) and HDL (0.03 mmol/L; 95% CI: 0.00, 0.06 mmol/L) cholesterol. Chocolate or cocoa improved FMD regardless of the dose consumed, whereas doses >50 mg epicatechin/d resulted in greater effects on systolic and diastolic BP. GRADE (Grading of Recommendations, Assessment, Development and Evaluation, a tool to assess quality of evidence and strength of recommendations) suggested low- to moderate-quality evidence of beneficial effects, with no suggestion of negative effects. The strength of evidence was lowered due to unclear reporting for allocation concealment, dropouts, missing data on outcomes, and heterogeneity in biomarker results in some studies.
We found consistent acute and chronic benefits of chocolate or cocoa on FMD and previously unreported promising effects on insulin and HOMA-IR. Larger, longer-duration, and independently funded trials are required to confirm the potential cardiovascular benefits of cocoa flavan-3-ols.

Download full-text


Available from: Jeffrey S Cohn, Jun 25, 2014
1 Follower
117 Reads
  • Source
    • "In this study, cocoa extract exhibited antioxidant activity, antihyperlipidemic and membrane stabilizing effect. The T. cacao extract may exert its protective effect by radical scavenging amongst other mechanisms; as intervention studies have suggested that cocoa has several beneficial effects on cardiovascular health, which includes the lowering of blood pressure, the improvement of vascular function and glucose metabolism, the reduction of platelet aggregation and adhesion (Sudano et al., 2012a) Cocoa and its flavanols increase nitric oxide (NO) bioavailability, activate nitric oxide synthase (NOS), and exert antioxidative, anti-inflammatory, and anti-platelet effects, which in turn improves vascular function, reduces blood pressure and therefore, explains the positive impact on clinical outcome proposed by epidemiological studies (Corti et al., 2009; Shrime et al., 2011; Hooper et al., 2012; Sudano et al., 2012b). More so, there is some evidence that flavanols and flavanol-rich foods including cocoa inhibit angiotensin-converting enzyme (ACE) activity in vitro (Actis-Goretta et al., 2003; Actis- Goretta et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The effect of Theobroma cacao (cocoa) polyphenol on isoproterenol-induced myocardial infarction in Wistar rats was studied. Polyphenol was extracted from cocoa using hydroalcohol solvent. Twenty four rats divided into six groups of four rats each were used for the study. Groups 3, 4, 5 and 6 were pretreated with the extract (300, 500 and 700 mg/kg) and 100 mg/kg of atenolol respectively before administration with isoproterenol. Group 1 served as normal control and group 2 was administered with isoproterenol without treatment. The activities of marker enzymes, aspartate amino transferase (AST), alanine amino transferase (ALT) and lactate dehydrogenase (LDH) in both serum and heart tissue homogenate were assayed. Cocoa polyphenol ameliorated the leakage of marker enzymes from the heart into the serum and also restored the levels of these enzymes in the cardiomyocytes. Histological examination of heart tissues revealed marked ability of the extract to reduce the progression of infarct lesions.
    Journal of Applied Pharmaceutical Science 08/2015; 5(07):76-83. DOI:10.7324/JAPS.2015.50713 · 0.47 Impact Factor
    • "Flavanols, including (−)-epicatechin (EC), and their related oligomers, the procyanidins, are plant-derived compounds that occur in substantial amounts in certain food and beverages , including apples, berries, tea, wine, and cocoa-derived products. In recent years, various dietary intervention studies have demonstrated improvements in vascular function, blood pressure, and platelet reactivity following the intake of flavanol-and procyanidin-containing foods [1] [2]. However, it remains to be fully established whether or not currently "
    [Show abstract] [Hide abstract]
    ABSTRACT: An understanding of the pharmacokinetics of structurally related (-)-epicatechin metabolites (SREM) is a prerequisite for considering cocoa flavanols (CF) in the context of dietary recommendations. The objective of this study was to compare the absorption, metabolism, and excretion of SREM in healthy young and elderly Caucasian men. Intra-individual variability of SREM was assessed in 7 young subjects, after consuming 10.7 mg CF/kg body weight (BW) on two occasions separated by one week. The effect of age on flavanols ADME was assessed in 20 young (18-35y) and 20 elderly (65-80y) healthy male subjects receiving 5.3 and 10.7 mg total CF/kg BW or 1 g of acetaminophen as a control to compare differences in Phase II metabolism on 3 days separated by 1 week of wash-out. Blood and urine samples were collected for 24 h post consumption. The intra-individual variation, measured as CV(%) with respect to the area-under-the-curve of the concentration over time (AUC(0-6h) ) of SREM, was 16%, whilst the inter-individual variation in AUC(0-6h) , was 38%, comparable to acetaminophen (39%). The AUC(0-6h) and the 24 h excretion of total SREM was not significantly different between young and elderly subjects. At the high intake amount, the AUC(0-6h) of (-)-epicatechin-3'-β-D-glucuronide was greater in elderly subjects, whereas the AUC(0-6h) of 3'-O-methyl-(-)-epicatechin-5-sulfate and 3'-O-methyl-(-)-epicatechin-7-sulfate as well as the 24 h urinary excretion of γ-valerolactone (γ-VL) metabolites were lower in the elderly. Cocoa flavanols are absorbed, metabolized, and excreted in healthy young and elderly subjects with relatively small differences between the two groups. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Molecular Nutrition & Food Research 05/2015; 59(8). DOI:10.1002/mnfr.201500091 · 4.60 Impact Factor
    • "Flavan-3-ols are associated with a number of health promoting effects in humans [4]. For example, a high consumption of cocoa, containing high amounts of monomeric and high-molecular procyanidins , was related to a reduction of cardiovascular disease risk factors [5]. However, comprehensive knowledge of the bioavailability and biotransformation of individual flavan-3- ols is required to unambiguously link their intake to bioactivity and thus to certain health effects. "
    [Show abstract] [Hide abstract]
    ABSTRACT: ScopeFlavan-3-ols are abundant polyphenols in human nutrition and are associated with beneficial health effects. The aim of this study was to comparatively investigate the metabolic fate of (-)-epicatechin, procyanidin B1, and polymeric procyanidins in a randomized cross-over study in humans.Methods and resultsParent compounds, conjugates, and microbial metabolites were determined in plasma, urine, and faeces by HPLC-MS and GC-MS/MS. Glucuronidated, sulfated, and methylated (-)-epicatechin and 5-(3′,4′-dihydroxyphenyl)-valerolactone were the dominant metabolites in blood and urine. In addition, minor amounts of procyanidin B1 and 4-hydroxy-5-(3′,4′-dihydroxyphenyl)valeric acid and their conjugated metabolites were detected. The formation of 5-(3′,4′-dihydroxyphenyl)-valerolactone and 4-hydroxy-5-(3′,4′-dihydroxyphenyl)valeric acid varied largely between individuals as well as with the degree of polymerization of flavan-3-ols. Monomer units were not detectable in plasma or urine after procyanidin B1 and polymeric procyanidin intake. No correlation was found between the intake of flavan-3-ols and the occurrence of phenolic acids in blood and urine or the phenolic compound profiles in faeces.Conclusion In addition to conjugated metabolites derived from the absorption of monomeric flavan-3-ols, 5-(3′,4′-dihydroxyphenyl)-valerolactone represents an important in vivo metabolite of (-)-epicatechin and procyanidin B1 produced by the gut microbiota.This article is protected by copyright. All rights reserved
    Molecular Nutrition & Food Research 12/2014; 59(4). DOI:10.1002/mnfr.201400422 · 4.60 Impact Factor
Show more